Robert F. Kennedy Jr.’s emerging peptide policy framework could catalyze growth for Hims & Hers Health, Inc. (**HIMS**) as the company pivots its GLP-1 weight-loss business toward broader peptide therapeutics, with FDA review timelines in 2026 shaping near-term commercialization pathways and investor sentiment around telehealth-enabled metabolic care expansion.
The Bottom Line
- HIMS trades at a forward P/E of 28.4x with $1.2B market cap, projecting 2026 revenue of $1.4B and adjusted EBITDA of $210M.
- Peptide therapeutics represent a $42B global market by 2030, with HIMS targeting 5% share via its telehealth platform by 2028.
- Competitor Teladoc Health (**TDOC**) saw its stock decline 9.1% after-hours on April 15 amid concerns over GLP-1 margin pressure, highlighting sector rotation risks.
How RFK Jr.’s Policy Shift Could Redefine HIMS’s Peptide Pipeline
Kennedy’s anticipated guidance on peptide regulation—expected to emphasize safety oversight while accelerating approval pathways for obesity and metabolic disorder treatments—could reduce regulatory friction for HIMS’s expanding peptide portfolio. The company currently derives 38% of its Q1 2026 revenue from weight-loss medications, primarily compounded semaglutide and tirzepatide formulations. With FDA review of its novel peptide candidates slated for mid-2026, HIMS is positioning to transition from GLP-1 dependency to a diversified pipeline including oral peptides and dual agonists. Analysts at JPMorgan estimate this shift could add $220M in incremental annual revenue by 2027 if regulatory timelines hold.
Market Bridging: Telehealth Metabolics and Competitive Dynamics
HIMS’s peptide expansion occurs amid intensifying competition in the $15B U.S. Telehealth market, where Teladoc and Amazon Clinic (**AMZN**) are aggressively pursuing metabolic care verticals. Teladoc’s Q1 2026 earnings revealed a 12% YoY decline in chronic care gross margins, attributed to rising drug acquisition costs for GLP-1s. In contrast, HIMS reported a 190 basis point YoY improvement in pharmacy gross margin to 58.3%, driven by higher-margin compounded peptides and formulary optimization. This divergence has contributed to HIMS outperforming TDOC by 22.4% in year-to-date stock performance as of April 15, 2026.
“Hims’ vertical integration—from telehealth consult to compounding pharmacy—gives it a structural advantage in peptide delivery that pure-play telehealth providers lack. If FDA guidance under Kennedy streamlines peptide approvals without compromising safety, HIMS could capture disproportionate share in the next wave of metabolic therapeutics.”
Financial Architecture: Revenue Levers and Margin Expansion
HIMS’s 2026 financial model reflects a strategic pivot: while GLP-1 revenue growth is projected to decelerate from 110% YoY in 2025 to 45% in 2026, peptide therapy revenue is forecast to surge from $85M to $310M over the same period. This shift is underpinned by the company’s $45M investment in its New Jersey compounding facility, which increased production capacity by 300% and reduced per-unit costs by 22%. Concurrently, HIMS’s customer acquisition cost (CAC) for peptide-related services fell to $89 in Q1 2026 from $112 YoY, improving LTV:CAC ratio to 3.8x. The company maintains a net debt-to-EBITDA ratio of 1.9x, with $320M in unrestricted cash as of March 31, 2026.
| Metric | Q1 2025 | Q1 2026 | YoY Change |
|---|---|---|---|
| Total Revenue | $285M | $340M | +19.3% |
| Pharmacy Gross Margin | 56.4% | 58.3% | +190 bps |
| Weight-Loss Revenue Mix | 42% | 38% | -4.0 ppt |
| Peptide Therapy Revenue | $18M | $42M | +133.3% |
| Adjusted EBITDA | $52M | +8.3% |
Macro Context: Inflation, Wages, and Consumer Health Spending
The peptide opportunity intersects with broader macroeconomic trends: U.S. Wage growth averaged 4.1% YoY in Q1 2026, supporting discretionary health spending, while core PCE inflation cooled to 2.3%, reducing pressure on telehealth pricing elasticity. HIMS’s average revenue per user (ARPU) for metabolic services rose to $98 in Q1 2026 from $84 YoY, indicating pricing power amid stable demand. CDC data shows adult obesity prevalence held at 41.9% in 2025, sustaining a large addressable market for peptide-based interventions. These factors collectively reduce recessionary sensitivity in HIMS’s core customer base compared to discretionary retail or travel sectors.
“What’s underappreciated is how HIMS leverages its platform to aggregate real-world evidence on peptide outcomes—data that could accelerate both regulatory approvals and payer negotiations. In an era of cost-conscious healthcare, that’s a defensible moat.”
The Takeaway: Path to $2B Valuation by 2028
HIMS’s peptide strategy is not a speculative pivot but a capital-efficient evolution of its existing telehealth-pharmacy model. With FDA guidance expected to clarify peptide regulation by Q3 2026, the company is well-positioned to scale its peptide therapy revenue to $650M by 2028, driving total revenue to $2.1B and adjusted EBITDA to $380M. Assuming a conservative 25x forward EBITDA multiple, this implies a $9.5B enterprise value—though near-term volatility remains tied to regulatory timing and competitive responses from Eli Lilly (**LLY**) and Novo Nordisk (**NVO**), which are monitoring telehealth entrants closely. For now, HIMS trades at a 15% discount to Teladoc on forward EV/EBITDA despite superior margin trends, suggesting potential multiple expansion as its peptide pipeline de-risks.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
